Verve Therapeutics Stock Working Capital
| VERV Stock | USD 5.55 0.01 0.18% |
Verve Therapeutics fundamentals help investors to digest information that contributes to Verve Therapeutics' financial success or failures. It also enables traders to predict the movement of Verve Stock. The fundamental analysis module provides a way to measure Verve Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Verve Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 499.8 M | 377 M | |
| Change In Working Capital | -2.3 M | -2.1 M |
Verve | Working Capital |
Verve Therapeutics Company Working Capital Analysis
Verve Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Verve Therapeutics Working Capital | 499.84 M |
Most of Verve Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Verve Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Verve Working Capital Driver Correlations
Understanding the fundamental principles of building solid financial models for Verve Therapeutics is extremely important. It helps to project a fair market value of Verve Stock properly, considering its historical fundamentals such as Working Capital. Since Verve Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Verve Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Verve Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Verve Net Invested Capital
Net Invested Capital |
|
As per the company's disclosures, Verve Therapeutics has a Working Capital of 499.84 M. This is 17.43% higher than that of the Biotechnology sector and 7.2% lower than that of the Health Care industry. The working capital for all United States stocks is 66.19% higher than that of the company.
Verve Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Verve Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Verve Therapeutics could also be used in its relative valuation, which is a method of valuing Verve Therapeutics by comparing valuation metrics of similar companies.Verve Therapeutics is currently under evaluation in working capital category among its peers.
Verve Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Verve Therapeutics from analyzing Verve Therapeutics' financial statements. These drivers represent accounts that assess Verve Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Verve Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 1.7B | 1.7B | 1.0B | 763.3M | 372.5M | 353.8M |
Verve Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Verve Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Verve Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Verve Fundamentals
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (4.29) % | ||||
| Current Valuation | 37.63 M | ||||
| Shares Outstanding | 88.8 M | ||||
| Shares Owned By Insiders | 5.04 % | ||||
| Shares Owned By Institutions | 90.12 % | ||||
| Number Of Shares Shorted | 14.02 M | ||||
| Price To Earning | 5.45 X | ||||
| Price To Book | 1.00 X | ||||
| Price To Sales | 15.21 X | ||||
| Revenue | 32.33 M | ||||
| Gross Profit | 9.48 M | ||||
| EBITDA | (228.66 M) | ||||
| Net Income | (198.71 M) | ||||
| Cash And Equivalents | 293.56 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 69.98 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 11.55 X | ||||
| Book Value Per Share | 5.56 X | ||||
| Cash Flow From Operations | (157.69 M) | ||||
| Short Ratio | 11.12 X | ||||
| Earnings Per Share | (2.35) X | ||||
| Target Price | 23.32 | ||||
| Number Of Employees | 274 | ||||
| Beta | 1.78 | ||||
| Market Capitalization | 491.93 M | ||||
| Total Asset | 647.39 M | ||||
| Retained Earnings | (743.01 M) | ||||
| Working Capital | 499.84 M | ||||
| Net Asset | 647.39 M |
About Verve Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Verve Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verve Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verve Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.